A Multicenter, Pivotal Phase 3 Study of Iomab-B Prior to Allogeneic Hematopoietic Cell Transplantation Versus Conventional Care in Older Subjects With Active, Relapsed or Refractory Acute Myeloid Leukemia

Trial Profile

A Multicenter, Pivotal Phase 3 Study of Iomab-B Prior to Allogeneic Hematopoietic Cell Transplantation Versus Conventional Care in Older Subjects With Active, Relapsed or Refractory Acute Myeloid Leukemia

Recruiting
Phase of Trial: Phase III

Latest Information Update: 25 Oct 2017

At a glance

  • Drugs Anti-CD45 monoclonal antibody BC8 I-131 (Primary) ; Fludarabine
  • Indications Acute myeloid leukaemia
  • Focus Registrational; Therapeutic Use
  • Acronyms SIERRA
  • Sponsors Actinium Pharmaceuticals
  • Most Recent Events

    • 25 Oct 2017 According to a Actinium Pharmaceuticals media release, the company has activated fifteen clinical trial sites in this study. The company is looking forward to adding additional clinical trial sites located in the U.S. and Canada and will provide update on the study by year end.
    • 21 Jun 2017 Planned primary completion date changed from 1 Apr 2018 to 1 Jun 2019.
    • 31 May 2017 According to an Actinium Pharmaceuticals media release, the company will host a webinar on Monday June 12, 2017 at 8 AM EST to provide an update on this trial.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top